A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3

Progressive familial intrahepatic cholestasis type 3 is caused by biallelic variations of ABCB4, most often (≥70%) missense. In this study, we examined the effects of 12 missense variations identified in progressive familial intrahepatic cholestasis type 3 patients. We classified these variations on the basis of the defects thus identified and explored potential rescue of trafficking‐defective mutants by pharmacological means. Variations were reproduced in the ABCB4 complementary DNA and the mutants, thus obtained, expressed in HepG2 and HEK293 cells. Three mutants were either fully (I541F and L556R) or largely (Q855L) retained in the endoplasmic reticulum, in an immature form. Rescue of the defect, i.e., increase in the mature form at the bile canaliculi, was obtained by cell treatments with cyclosporin A or C and, to a lesser extent, B, D, or H. Five mutations with little or no effect on ABCB4 expression at the bile canaliculi caused a decrease (F357L, T775M, and G954S) or almost absence (S346I and P726L) of phosphatidylcholine secretion. Two mutants (T424A and N510S) were normally processed and expressed at the bile canaliculi, but their stability was reduced. We found no defect of the T175A mutant or of R652G, previously described as a polymorphism. In patients, the most severe phenotypes appreciated by the duration of transplant‐free survival were caused by ABCB4 variants that were markedly retained in the endoplasmic reticulum and expressed in a homozygous status. Conclusion: ABCB4 variations can be classified as follows: nonsense variations (I) and, on the basis of current findings, missense variations that primarily affect the maturation (II), activity (III), or stability (IV) of the protein or have no detectable effect (V); this classification provides a strong basis for the development of genotype‐based therapies. (Hepatology 2016;63:1620‐1631)

[1]  K. Lindor,et al.  Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.

[2]  J. Stindt,et al.  A Mutation within the Extended X Loop Abolished Substrate-induced ATPase Activity of the Human Liver ATP-binding Cassette (ABC) Transporter MDR3* , 2014, The Journal of Biological Chemistry.

[3]  C. Housset,et al.  ABCB4: Insights from pathobiology into therapy. , 2014, Clinics and research in hepatology and gastroenterology.

[4]  G. Bolbach,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Phosphorylation of ABCB4 Impacts Its Function: Insights From Disease-Causing Mutations , 2014 .

[5]  P. Jara,et al.  Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity , 2014, Gut.

[6]  J. Boyer,et al.  Peroxisome proliferator‐activated receptor α activates human multidrug resistance transporter 3/ATP‐binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion , 2014, Hepatology.

[7]  M. Rastaldi,et al.  Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction , 2013, European Journal of Human Genetics.

[8]  A. Cadoret,et al.  Vitamin D Nuclear Receptor Deficiency Promotes Cholestatic Liver Injury by Disruption of Biliary Epithelial Cell Junctions in Mice , 2013, Hepatology.

[9]  E. Jacquemin,et al.  Clinical utility gene card for: Progressive familial intrahepatic cholestasis type 3 , 2013, European Journal of Human Genetics.

[10]  P. Böelle,et al.  Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients , 2013, Hepatology.

[11]  T. Miyazaki,et al.  AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid , 2013 .

[12]  C. Housset,et al.  Effects of Cellular, Chemical, and Pharmacological Chaperones on the Rescue of a Trafficking-defective Mutant of the ATP-binding Cassette Transporter Proteins ABCB1/ABCB4* , 2011, The Journal of Biological Chemistry.

[13]  K. Linton,et al.  Structure of ABC transporters. , 2011, Essays in biochemistry.

[14]  F. Callea,et al.  Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  D. Consonni,et al.  Clinical Features and Genotype-Phenotype Correlations in Children With Progressive Familial Intrahepatic Cholestasis Type 3 Related to ABCB4 Mutations , 2011, Journal of pediatric gastroenterology and nutrition.

[16]  T. Pusl,et al.  ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

[17]  D. Wendum,et al.  Combined features of low phospholipid‐associated cholelithiasis and progressive familial intrahepatic cholestasis 3 , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[18]  E. Jacquemin,et al.  A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature , 2009, Hepatology.

[19]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[20]  D. Clarke,et al.  Mutational analysis of ABC proteins. , 2008, Archives of biochemistry and biophysics.

[21]  M. Ziol,et al.  ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. , 2008, Gastroenterology.

[22]  A. Floreani,et al.  Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[23]  M. Seia,et al.  Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3) , 2007, European Journal of Human Genetics.

[24]  K. Yoshizato,et al.  Bezafibrate induces multidrug‐resistance P‐Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[25]  D. Clarke,et al.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.

[26]  M. Haberl,et al.  Genetic Variability, Haplotype Structures, and Ethnic Diversity of Hepatic Transporters MDR3 (ABCB4) and Bile Salt Export Pump (ABCB11) , 2006, Drug Metabolism and Disposition.

[27]  P. Meier,et al.  BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis , 2004, Hepatology.

[28]  P. Meier,et al.  Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. , 2004, Pharmacogenetics.

[29]  R. Blevins,et al.  Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.

[30]  Bryan Goodwin,et al.  Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. , 2003, The Journal of clinical investigation.

[31]  P. Boelle,et al.  ABCB4 gene mutation-associated cholelithiasis in adults. , 2003, Gastroenterology.

[32]  B. Staels,et al.  Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.

[33]  O. Rosmorduc,et al.  MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. , 2001, Gastroenterology.

[34]  P. Bosma,et al.  The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. , 2001, Gastroenterology.

[35]  G. Hooiveld,et al.  3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. , 1999, Gastroenterology.

[36]  S. Cogoi,et al.  Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin‐treated rat , 1999, Hepatology.

[37]  A. Rigotti,et al.  Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. , 1996, The Biochemical journal.

[38]  K. Linton,et al.  AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Molecular Mechanistic Explanation for the Spectrum of Cholestatic Disease Caused by the S320F Variant of ABCB4 , 2014 .